|
1
|
Li J, Yang Z, Li Y, Xia J, Li D, Li H, Ren
M, Liao Y, Yu S, Chen Y, et al: Cell apoptosis, autophagy and
necroptosis in osteosarcoma treatment. Oncotarget. 7:44763–44778.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Endo-Munoz L, Cumming A, Sommerville S,
Dickinson I and Saunders NA: Osteosarcoma is characterised by
reduced expression of markers of osteoclastogenesis and antigen
presentation compared with normal bone. Br J Cancer. 103:73–81.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vos HI, Coenen MJ, Guchelaar HJ and Te Loo
DM: The role of pharmacogenetics in the treatment of osteosarcoma.
Drug Discov Today. 21:1775–1786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amankwah EK, Conley AP and Reed DR:
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol.
5:147–162. 2013.PubMed/NCBI
|
|
5
|
Bishop MW, Janeway KA and Gorlick R:
Future directions in the treatment of osteosarcoma. Curr Opin
Pediatr. 28:26–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mayer MN and Grier CK: Palliative
radiation therapy for canine osteosarcoma. Can Vet J. 47:707–709.
2006.PubMed/NCBI
|
|
8
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ning Q, Liu YF, Ye PJ, Gao P, Li ZP, Tang
SY, He DX, Tang SS, Wei H and Yu CY: Delivery of liver-specific
miRNA-122 using a targeted macromolecular prodrug toward
synergistic therapy for hepatocellular carcinoma. ACS Appl Mater
Interfaces. 11:10578–10588. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin X, Wang S, Sun M, Zhang C, Wei C, Yang
C, Dou R, Liu Q and Xiong B: miR-195-5p/NOTCH2-mediated EMT
modulates IL-4 secretion in colorectal cancer to affect M2-like TAM
polarization. J Hematol Oncol. 12:202019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zuo S, Dai G, Wang L, Wen Y, Huang Z, Yang
W, Ma W and Ren X: Suppression of angiogenesis and tumor growth by
recombinant T4 phages displaying extracellular domain of vascular
endothelial growth factor receptor 2. Arch Virol. 164:69–82. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weidhaas J: Using microRNAs to understand
cancer biology. Lancet Oncol. 11:106–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nana-Sinkam SP and Croce CM: MicroRNA
regulation of tumorigenesis, cancer progression and interpatient
heterogeneity: Towards clinical use. Genome Biol. 15:4452014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang D, Wang F, Wu W, Lian C and Liu E:
MicroRNA-429 inhibits cancer cell proliferation and migration by
targeting the AKT1 in melanoma. Cancer Biomark. 26:63–68. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zong M, Liu Y, Zhang K, J Y and Chen L:
The effects of miR-429 on cell migration and invasion by targeting
Slug in esophageal squamous cell carcinoma. Pathol Res Pract.
215:1525262019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su Z, Jiang G, Chen J, Liu X, Zhao H, Fang
Z, He Y, Jiang X and Xu G: MicroRNA-429 inhibits cancer cell
proliferation and migration by targeting AKT1 in renal cell
carcinoma. Mol Clin Oncol. 12:75–80. 2020.PubMed/NCBI
|
|
18
|
Liu X, Liu Y, Wu S, Shi X, Li L, Zhao J
and Xu H: Tumor-suppressing effects of miR-429 on human
osteosarcoma. Cell Biochem Biophys. 70:215–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu SL, Koo H, Lee HY, Yeom YI, Lee DC and
Kang J: Recombinant cell-permeable HOXA9 protein inhibits NSCLC
cell migration and invasion. Cell Oncol (Dordr). 42:275–285. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Makabe T, Arai E, Hirano T, Ito N,
Fukamachi Y, Takahashi Y, Hirasawa A, Yamagami W, Susumu N, Aoki D,
et al: Genome-wide DNA methylation profile of early-onset
endometrial cancer: Its correlation with genetic aberrations and
comparison with late-onset endometrial cancer. Carcinogenesis.
40:611–623. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z,
Phuc Khoa LT, Jang Y, Cai S, Witkin M, et al: HOXA9 reprograms the
enhancer landscape to promote leukemogenesis. Cancer Cell.
34:643–658, e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Wang Y, Yang H, Zhao L, Song R, Tan
H and Wang L: MicroRNA 873 targets HOXA9 to inhibit the aggressive
phenotype of osteosarcoma by deactivating the Wnt/β catenin
pathway. Int J Oncol. 54:1809–1820. 2019.PubMed/NCBI
|
|
23
|
Yu J, Tian X, Chang J, Liu P and Zhang R:
RUNX3 inhibits the proliferation and metastasis of gastric cancer
through regulating miR-182/HOXA9. Biomed Pharmacother. 96:782–791.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng DH, Wang X, Lu LN, Chen DL, Chen JM,
Lin FM and Xu XB: MiR-638 serves as a tumor suppressor by targeting
HOXA9 in glioma. Eur Rev Med Pharmacol Sci. 22:7798–7806.
2018.PubMed/NCBI
|
|
25
|
Zhang ZF, Wang YJ, Fan SH, Du SX, Li XD,
Wu DM, Lu J and Zheng YL: MicroRNA-182 downregulates Wnt/β-catenin
signaling, inhibits proliferation, and promotes apoptosis in human
osteosarcoma cells by targeting HOXA9. Oncotarget. 8:101345–101361.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gianferante DM, Mirabello L and Savage SA:
Germline and somatic genetics of osteosarcoma - connecting
aetiology, biology and therapy. Nat Rev Endocrinol. 13:480–491.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lindsey BA, Markel JE and Kleinerman ES:
Osteosarcoma overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gorlick R and Khanna C: Osteosarcoma. J
Bone Miner Res. 25:683–691. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Zhang C, Wang C, Sun J, Wang D,
Zhao Y and Xu X: miR-210 promotes human osteosarcoma cell migration
and invasion by targeting FGFRL1. Oncol Lett. 16:2229–2236.
2018.PubMed/NCBI
|
|
31
|
Wang L, Hu K and Chao Y: MicroRNA-1301
inhibits migration and invasion of osteosarcoma cells by targeting
BCL9. Gene. 679:100–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alvarez-Garcia I and Miska EA: MicroRNA
functions in animal development and human disease. Development.
132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu G, Zheng H, Xu J, Guo Y, Zheng G, Ma C,
Hao S, Liu X, Chen H, Wei S, et al: miR-429 suppresses cell growth
and induces apoptosis of human thyroid cancer cells by targeting
ZEB1. Artif Cells Nanomed Biotechnol. 47:548–554. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen F, Zheng H, Zhou L, Li W and Xu X:
Overexpression of MALAT1 contributes to cervical cancer progression
by acting as a sponge of miR-429. J Cell Physiol. 234:11219–11226.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu D, Song L, Dai Z, Guan H, Kang H,
Zhang Y, Yan W, Zhao X and Zhang S: MiR-429 suppresses
neurotrophin-3 to alleviate perineural invasion of pancreatic
cancer. Biochem Biophys Res Commun. 505:1077–1083. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Deng Y, Luan F, Zeng L, Zhang Y and Ma K:
MiR-429 suppresses the progression and metastasis of osteosarcoma
by targeting ZEB1. EXCLI J. 16:618–627. 2017.PubMed/NCBI
|
|
37
|
Pineault N, Helgason CD, Lawrence HJ and
Humphries RK: Differential expression of Hox, Meis1, and Pbx1 genes
in primitive cells throughout murine hematopoietic ontogeny. Exp
Hematol. 30:49–57. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schneider E, Staffas A, Röhner L, Malmberg
ED, Ashouri A, Krowiorz K, Pochert N, Miller C, Wei SY, Arabanian
L, et al: Micro-ribonucleic acid-155 is a direct target of Meis1,
but not a driver in acute myeloid leukemia. Haematologica.
103:246–255. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou L, Wang Y, Zhou M, Zhang Y, Wang P,
Li X, Yang J, Wang H and Ding Z: HOXA9 inhibits HIF-1α-mediated
glycolysis through interacting with CRIP2 to repress cutaneous
squamous cell carcinoma development. Nat Commun. 9:14802018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chong GO, Jeon HS, Han HS, Son JW, Lee YH,
Hong DG, Park HJ, Lee YS and Cho YL: Overexpression of
microRNA-196b accelerates invasiveness of cancer cells in recurrent
epithelial ovarian cancer through regulation of homeobox A9. Cancer
Genomics Proteomics. 14:137–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Thomsen CB, Andersen RF, Steffensen KD,
Adimi P and Jakobsen A: Delta tocotrienol in recurrent ovarian
cancer. A phase II trial. Pharmacol Res. 141:392–396. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bhatlekar S, Ertel A, Gonye GE, Fields JZ
and Boman BM: Gene expression signatures for HOXA4, HOXA9, and
HOXD10 reveal alterations in transcriptional regulatory networks in
colon cancer. J Cell Physiol. 234:13042–13056. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoshida A, Fujiwara T, Uotani K, Morita T,
Kiyono M, Yokoo S, Hasei J, Nakata E, Kunisada T and Ozaki T:
Clinical and functional significance of intracellular and
extracellular microRNA-25-3p in osteosarcoma. Acta Med Okayama.
72:165–174. 2018.PubMed/NCBI
|
|
44
|
Kureel J, John AA, Prakash R and Singh D:
MiR 376c inhibits osteoblastogenesis by targeting Wnt3 and
ARF-GEF-1-facilitated augmentation of beta-catenin transactivation.
J Cell Biochem. 119:3293–3303. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kushlinskii NE, Fridman MV and Braga EA:
Molecular mechanisms and microRNAs in osteosarcoma pathogenesis.
Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu X, Li L, Lv L, Chen D, Shen L and Xie
Z: Apigenin inhibits the proliferation and invasion of osteosarcoma
cells by suppressing the Wnt/β-catenin signaling pathway. Oncol
Rep. 34:1035–1041. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Graziano AC, Cardile V, Avola R, Vicario
N, Parenti C, Salvatorelli L, Magro G and Parenti R: Wilms' tumor
gene 1 silencing inhibits proliferation of human osteosarcoma MG-63
cell line by cell cycle arrest and apoptosis activation.
Oncotarget. 8:13917–13931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:E5564–E5573. 2014. View Article : Google Scholar : PubMed/NCBI
|
